Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Neuromuscular Junction And Blockade01:29

Neuromuscular Junction And Blockade

The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Self-Reported Flourishing Among U.S. Surgeons: A National Physician Survey.

Journal of the American College of Surgeons·2026
Same author

American Journal of Transplantation at 25 years: A trusted voice.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Dual costimulation blockade with the CD154-specific fusion protein dazodalibep and belatacept for prophylaxis of kidney allograft rejection.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

A Report of Four Depletional Induction Strategies in Non-Human Primate Islet Xenotransplantation.

Xenotransplantation·2026
Same author

Costimulatory blockade and infectious risk in solid organ transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Corrigendum to "Antibodies to angiotensin II type 1 receptor and endothelin type A receptor are associated with cytokine production enriched for type 2 immune response and antibody production in pediatric kidney transplant recipients" [American Journal of Transplantation. Volume 25, Issue 11, November 2025, Pages 2329-2344].

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2025

Related Experiment Video

Updated: May 7, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Costimulation blockade: towards clinical application.

Timothy A Weaver1, Ali H Charafeddine, Allan D Kirk

  • 1The Transplantation Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA.

Frontiers in Bioscience : a Journal and Virtual Library
|November 6, 2007
PubMed
Summary
This summary is machine-generated.

Costimulation blockade targets specific immune pathways to prevent organ transplant rejection. This approach offers improved antigen-specific control while minimizing broad immunosuppression, enhancing transplant success.

More Related Videos

Transcranial Direct Current Stimulation and Simultaneous Functional Magnetic Resonance Imaging
13:35

Transcranial Direct Current Stimulation and Simultaneous Functional Magnetic Resonance Imaging

Published on: April 27, 2014

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Related Experiment Videos

Last Updated: May 7, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Transcranial Direct Current Stimulation and Simultaneous Functional Magnetic Resonance Imaging
13:35

Transcranial Direct Current Stimulation and Simultaneous Functional Magnetic Resonance Imaging

Published on: April 27, 2014

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Area of Science:

  • Immunology
  • Transplantation Biology
  • Drug Discovery

Background:

  • Organ transplantation success relies on preventing immune rejection.
  • Current immunosuppressants broadly suppress immunity, affecting protective responses.
  • Costimulatory receptors are crucial for productive immune responses.

Purpose of the Study:

  • To review the biology and therapeutic potential of costimulation blockade for organ transplant rejection.
  • To highlight specific costimulatory pathways (CD28/CD80-CD86 and CD40-CD154) as therapeutic targets.
  • To discuss the experimental and clinical data supporting costimulation blockade.

Main Methods:

  • Review of basic costimulation biology.
  • Analysis of experimental data on costimulation blockade in preventing rejection.
  • Discussion of clinical trial data for costimulation blockade therapies.
  • Focus on CD28/CD80-CD86 and CD40-CD154 pathways.

Main Results:

  • Costimulation blockade can specifically influence immune responses to transplanted organs.
  • Targeting costimulatory pathways offers a strategy to prevent rejection with reduced broad immunosuppression.
  • Clinical data supports the validity of CD28/CD80-CD86 and CD40-CD154 pathways as therapeutic targets.

Conclusions:

  • Costimulation blockade is a promising therapeutic strategy for organ transplantation.
  • This approach aims to improve transplant outcomes by achieving antigen-specific immune control.
  • Future research may identify novel costimulatory pathways for therapeutic intervention.